Dewdney B, Jenkins MR, Best SA, Freytag S, Prasad K, Holst J, Endersby R, Johns TG. From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress. Signal Transduction and Targeted Therapy. 2023;8(1):10.1038/s41392-023-01637-8
Prasad K, Cross RS, Jenkins MR. Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy. Molecular Oncology. 2023;17(6):10.1002/1878-0261.13420
Hansford J, Valvi S, de Boer J, McCowage G, Govender D, Kirby M, Ziegler D, Manoharan N, Hassall T, Wainwright B, Alvaro F, Wood PJ, Eisenstat D, Quang DAK, Jenkins M, Dun M, Laughton SJ, Endersby R, Dodgshun A, Gottardo N. “If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials. The Medical Journal of Australia. 2024;221(10):10.5694/mja2.52506
Lertsumitkul L, Iliopoulos M, Wang SS, McArthur SJ, Ebert LM, Davenport AJ, Endersby R, Hansford JR, Drummond KJ, Cross R, Jenkins MR. EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses. Journal for ImmunoTherapy of Cancer. 2024;12(8):10.1136/jitc-2024-009486
Davenport AJ, Lertsumitkul L, Cross RS, Jenkins MR. IMMU-10. DEVELOPING NOVEL CHIMERIC ANTIGEN RECEPTOR THERAPIES FOR PAEDIATRIC HIGH GRADE GLIOMA. Neuro-Oncology. 2024;26(Supplement_4):10.1093/neuonc/noae064.381
Jenkins MR, Drummond KJ. CAR T-Cell Therapy for Glioblastoma. New England Journal of Medicine. 2024;390(14):10.1056/nejme2401307
Mehta PH, Trollope GS, Leung P, Chinni SS, Iasinskaia A, Harrison AJ, Hughes‐Parry H, Jenkins MR, Kershaw MH, Jaworowski A, Slaney CY, Koldej RM, Ritchie DS, Quinn KM. Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals. Clinical & Translational Immunology. 2024;13(12):10.1002/cti2.70016
Ralalage PB, Mitchell T, Zammit C, Baynam G, Kowal E, Masey L, McGaughran J, Boughtwood T, Jenkins M, Pratt G, Ferdinand A. “Equity” in genomic health policies: a review of policies in the international arena. Frontiers in Public Health. 2024;12:10.3389/fpubh.2024.1464701
Reis ALM, Rapadas M, Hammond JM, Gamaarachchi H, Stevanovski I, Ayuputeri Kumaheri M, Chintalaphani SR, Dissanayake DSB, Siggs OM, Hewitt AW, Llamas B, Brown A, Baynam G, Mann GJ, McMorran BJ, Easteal S, Hermes A, Jenkins MR, Patel HR, Deveson IW. The landscape of genomic structural variation in Indigenous Australians. Nature. 2023;624(7992):10.1038/s41586-023-06842-7
Silcocks M, Farlow A, Hermes A, Tsambos G, Patel HR, Huebner S, Baynam G, Jenkins MR, Vukcevic D, Easteal S, Leslie S. Indigenous Australian genomes show deep structure and rich novel variation. Nature. 2023;624(7992):10.1038/s41586-023-06831-w
Wang SS, Pandey K, Watson KA, Abbott RC, Mifsud NA, Gracey FM, Ramarathinam SH, Cross RS, Purcell AW, Jenkins MR. Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma. Molecular Therapy Oncology. 2023;30:10.1016/j.omto.2023.08.005
Chandler NJ, Davey AS, Elazar A, Weinstein JY, Nguyen JV, Trenker R, Cross RS, Jenkins MR, Call ME, Fleishman SJ, Call MJ. De novo -designed transmembrane domains tune chimeric antigen receptor function. Acta Crystallographica Section A: Foundations and advances. 2023;79(a2):10.1107/s2053273323086722
